Clinical presentation, diagnosis and management of therapy‐related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly‐ADP‐ribose polymerase inhibitors: A single‐center experience-Reference-Cited by-同舟云学术

Clinical presentation, diagnosis and management of therapy‐related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly‐ADP‐ribose polymerase inhibitors: A single‐center experience

Published:2020-09-16 Issue:1 Volume:148 Page:170-177
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Todisco Elisabetta¹,Gigli Federica¹,Mantiero Mara²,Sammassimo Simona¹,Pastano Rocco¹,Ronchini Chiara³^ORCID,Parma Gabriella⁴,Lapresa Maria Teresa⁴,Iori Anna Paola⁵,Bertolini Francesco⁶,Corsini Chiara⁶,Gregato Giuliana⁶,Poletti Claudia⁶,Colombo Nicoletta⁷,Tarella Corrado¹⁸

Affiliation:

1. Onco‐Hematology Division, IEO European Institute of Oncology IRCCS Milan Italy

2. Gynecologic Oncology Unit Fondazione IRCCS National Cancer Institute Milan Italy

3. Laboratory of Clinical Genomics, IEO European Institute of Oncology IRCCS Milan Italy

4. Department of Gynecology, IEO European Institute of Oncology IRCCS Milan Italy

5. Department of Cellular Biotechnologies and Hematology Sapienza University Rome Italy

6. Laboratory of Hematology‐Oncology, IEO European Institute of Oncology IRCCS Milan Italy

7. Gynecologic Cancer Program European Institute of Oncology and University of Milan‐Bicocca Milan Italy

8. Department of Health Sciences University of Milan Milan Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33269

Reference25 articles.

1. Cancer statistics, 2013

2. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

3. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

4. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

5. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Therapy‐related myeloid neoplasms after treatment for ovarian cancer: A retrospective single‐center case series;Journal of Obstetrics and Gynaecology Research;2024-04-17

3. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer;International Journal of Molecular Sciences;2024-03-09

4. Myeloid neoplasms post PARP inhibitors for ovarian cancer;International Journal of Gynecologic Cancer;2023-01-27

5. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience;Clinical Cancer Research;2022-10-06